| Literature DB >> 36180922 |
Ana Lopez-de-Andres1, Rodrigo Jimenez-Garcia2, Valentin Hernández-Barrera3, Javier de-Miguel-Díez4, Jose M de-Miguel-Yanes5, David Martinez-Hernandez1, David Carabantes-Alarcon1, Jose J Zamorano-Leon1, Concepción Noriega6.
Abstract
BACKGROUND: We performed a study to assess sex-differences in incidence (2016-2020), clinical characteristics, use of therapeutic procedures, and in-hospital outcomes in patients with infective endocarditis (IE) according to T2DM status.Entities:
Keywords: Diabetes; Hospitalization; Infective endocarditis; Mortality; Sex differences
Mesh:
Year: 2022 PMID: 36180922 PMCID: PMC9524731 DOI: 10.1186/s12933-022-01633-2
Source DB: PubMed Journal: Cardiovasc Diabetol ISSN: 1475-2840 Impact factor: 8.949
Incidence, clinical characteristics and in-hospital outcomes of patients hospitalized with infective endocarditis in Spain from 2016 to 2020 according to T2DM status
| 2016 | 2017 | 2018 | 2019 | 2020 | p-value | ||
|---|---|---|---|---|---|---|---|
| N, (incidence per 100,000 subjects per year) | T2DM | 468 (15.29) | 534 (17.45) | 538 (18.06) | 615 (21.21) | 513 (17.69) | < 0.001 |
| No T2DM | 1385 (6.12) | 1411 (6.23) | 1615 (6.93) | 1518 (6.33) | 1361 (5.68) | 0.111 | |
| N, (incidence per 100,000 women per year) | T2DM | 154 (10.64) | 165 (11.4) | 160 (11.36) | 196 (14.3) | 164 (11.96) | 0.056 |
| No T2DM | 458 (3.82) | 481 (4.01) | 577 (4.69) | 490 (3.87) | 463 (3.66) | 0.385 | |
| N, (incidence per 100,000 men per year) | T2DM | 314 (19.47) | 369 (22.88) | 378 (24.07) | 419 (27.42) | 349 (22.84) | 0.003 |
| No T2DM | 927 (8.7) | 930 (8.72) | 1038 (9.44) | 1028 (9.07) | 898 (7.92) | 0.161 | |
| Age, mean (SD) | T2DM | 72.94 (10.09) | 72.5 (9.62) | 72.78 (9.62) | 72.53 (9.99) | 73.66 (9.58) | 0.298 |
| No T2DM | 69.76 (13.23) | 69.26 (13.19) | 70.16 (13.54) | 69.47 (13.23) | 69.99 (12.7) | 0.330 | |
| CCI index, mean (SD) | T2DM | 1.26 (1.07) | 1.4 (1) | 1.5 (1.13) | 1.5 (1.1) | 1.56 (1.11) | < 0.001 |
| No T2DM | 1.06 (1.04) | 1.16 (1.05) | 1.15 (1.04) | 1.1 (1.03) | 1.2 (1.08) | 0.006 | |
| Previous aortic valve disease, n (%) | T2DM | 115 (24.57) | 146 (27.34) | 118 (21.93) | 175 (28.46) | 135 (26.32) | 0.109 |
| No T2DM | 356 (25.7) | 412 (29.2) | 469 (29.04) | 446 (29.38) | 455 (33.43) | 0.001 | |
| Previous mitral valve disease, n (%) | T2DM | 110 (23.5) | 121 (22.66) | 145 (26.95) | 156 (25.37) | 138 (26.9) | 0.378 |
| No T2DM | 381 (27.51) | 396 (28.07) | 457 (28.3) | 432 (28.46) | 430 (31.59) | 0.138 | |
| Previous pulmonic valve disease, n (%) | T2DM | 0 (0) | 3 (0.56) | 0 (0) | 1 (0.16) | 0 (0) | 0.080 |
| No T2DM | 4 (0.29) | 5 (0.35) | 3 (0.19) | 1 (0.07) | 5 (0.37) | 0.430 | |
| Previous tricuspid valve disease, n (%) | T2DM | 24 (5.13) | 28 (5.24) | 44 (8.18) | 60 (9.76) | 42 (8.19) | 0.011 |
| No T2DM | 74 (5.34) | 97 (6.87) | 138 (8.54) | 126 (8.3) | 140 (10.29) | < 0.001 | |
| Prosthetic valve carriers, n (%) | T2DM | 59 (12.61) | 44 (8.24) | 57 (10.59) | 53 (8.62) | 43 (8.38) | 0.085 |
| No T2DM | 132 (9.53) | 140 (9.92) | 144 (8.92) | 123 (8.1) | 128 (9.4) | 0.483 | |
| LOHS, Median (IQR) | T2DM | 19 (27) | 17 (27) | 18.5 (24) | 19 (25) | 18 (23) | 0.633 |
| No T2DM | 19 (24) | 19 (27) | 19 (27) | 19 (24) | 19 (23) | 0.994 | |
| IHM, n (%) | T2DM | 89 (19.02) | 104 (19.48) | 93 (17.29) | 104 (16.91) | 102 (19.88) | 0.622 |
| No T2DM | 226 (16.32) | 207 (14.67) | 280 (17.34) | 276 (18.18) | 249 (18.3) | 0.058 |
T2DM: Type 2 diabetes mellitus; CCI: Charlson comorbidity index; LOHS: Length of hospital stay; IHM: in-hospital mortality
Fig. 1Distribution of more frequent pathogens in patients with and without T2DM with infective endocarditis in Spain (2016–2020)
Distribution of study covariates and hospital outcomes of WOMEN with and without T2DM with infective endocarditis in Spain (2016–2020), before and after propensity score matching (PSM)
| Before PSM | After PSM | |||||
|---|---|---|---|---|---|---|
| T2DM | No T2DM | p-value | T2DM | No T2DM | p-value | |
| N, (incidence per 100,000 women per year) | 839 (11.91) | 2469 (4.01) | < 0.001 | 839 | 839 | NA |
| Age, mean (SD) | 75.58 (9) | 73.13 (12.57) | < 0.001 | 75.58 (9) | 76.81 (10.12) | 0.008 |
| 40–66 years old, n (%) | 122 (14.54) | 678 (27.46) | < 0.001 | 122 (14.54) | 122 (14.54) | 0.008 |
| 67–75 years old, n (%) | 264 (31.47) | 568 (23.01) | 264 (31.47) | 209 (24.91) | ||
| ≥ 76 years old, n (%) | 453 (53.99) | 1223 (49.53) | 453 (53.99) | 508 (60.55) | ||
| Acute renal disease, n (%) | 205 (24.43) | 489 (19.81) | 0.004 | 205 (24.43) | 200 (23.84) | 0.775 |
| Chronic renal disease, n (%) | 257 (30.63) | 394 (15.96) | < 0.001 | 257 (30.63) | 244 (29.08) | 0.488 |
| Congestive heart failure, n (%) | 146 (17.4) | 254 (10.29) | < 0.001 | 146 (17.4) | 129 (15.38) | 0.262 |
| COPD, n (%) | 35 (4.17) | 74 (3) | 0.100 | 35 (4.17) | 37 (4.41) | 0.810 |
| Dementia, n (%) | 34 (4.05) | 60 (2.43) | 0.015 | 34 (4.05) | 31 (3.69) | 0.704 |
| Atrial fibrillation, n (%) | 319 (38.02) | 872 (35.32) | 0.159 | 319 (38.02) | 308 (36.71) | 0.579 |
| COVID-19, n (%) | 6 (0.72) | 13 (0.53) | 0.532 | 6 (0.72) | 6 (0.72) | 0.999 |
| Ischemic heart disease, n (%) | 114 (13.59) | 229 (9.28) | < 0.001 | 114 (13.59) | 110 (13.11) | 0.774 |
| Previous aortic valve disease, n (%) | 206 (24.55) | 633 (25.64) | 0.533 | 206 (24.55) | 196 (23.36) | 0.567 |
| Previous mitral valve disease, n (%) | 268 (31.94) | 788 (31.92) | 0.988 | 268 (31.94) | 263 (31.35) | 0.793 |
| Previous pulmonic valve disease, n (%) | 2 (0.24) | 6 (0.24) | 0.981 | 2 (0.24) | 1 (0.12) | 0.563 |
| Previous tricuspid valve disease, n (%) | 94 (11.2) | 233 (9.44) | 0.139 | 94 (11.2) | 97 (11.56) | 0.818 |
| Prosthetic valve carriers, n (%) | 83 (9.89) | 241 (9.76) | 0.912 | 83 (9.89) | 87 (10.37) | 0.746 |
| CCI index, mean (SD) | 1.41 (0.99) | 1.13 (1) | < 0.001 | 1.41 (0.99) | 1.32 (1.07) | 0.097 |
| Periannular complications / atrioventricular block, n (%) | 45 (5.36) | 93 (3.77) | 0.046 | 45 (5.36) | 32 (3.81) | 0.129 |
| Septic arterial embolism, n (%) | 35 (4.17) | 103 (4.17) | 0.999 | 35 (4.17) | 23 (2.74) | 0.109 |
| Cardiogenic shock, n (%) | 14 (1.67) | 52 (2.11) | 0.434 | 14 (1.67) | 16 (1.91) | 0.713 |
| Dialysis, n (%) | 64 (7.63) | 105 (4.25) | < 0.001 | 64 (7.63) | 33 (3.93) | 0.001 |
| Heart valve surgery (aortic, mitral, tricuspid, pulmonary), n (%) | 121 (14.42) | 414 (16.77) | 0.111 | 121 (14.42) | 108 (12.87) | 0.355 |
| Mechanical ventilation, n (%) | 87 (10.37) | 254 (10.29) | 0.946 | 87 (10.37) | 74 (8.82) | 0.281 |
| Pacemaker implantation, n (%) | 41 (4.89) | 97 (3.93) | 0.231 | 41 (4.89) | 32 (3.81) | 0.290 |
| LOHS, Median (IQR) | 18 (25) | 18 (26) | 0.778 | 18 (25) | 18 (26) | 0.823 |
| IHM, n (%) | 190 (22.65) | 498 (20.17) | 0.127 | 190 (22.65) | 187 (22.29) | 0.861 |
T2DM: Type 2 diabetes mellitus; CCI: Charlson comorbidity index; COPD: chronic obstructive pulmonary disease; LOHS: Length of hospital stay; IHM: in-hospital mortality
Distribution of study covariates and hospital outcomes of MEN with and without T2DM with infective endocarditis in Spain (2016–2020), before and after propensity score matching (PSM)
| BEFORE PSM | AFTER PSM | |||||
|---|---|---|---|---|---|---|
| T2DM | No T2DM | p-value | T2DM | No T2DM | p-value | |
| N, (incidence per 100,000 men per year) | 1829 (23.29) | 4821 (8.77) | < 0.001 | 1829 | 1829 | NA |
| Age, mean (SD) | 71.61 (9.88) | 67.99 (13.17) | < 0.001 | 71.61 (9.88) | 72.86 (11.07) | < 0.001 |
| 40–66 years old, n (%) | 543 (29.69) | 2066 (42.85) | < 0.001 | 543 (29.69) | 489 (26.74) | < 0.001 |
| 67–75 years old, n (%) | 590 (32.26) | 1147 (23.79) | 590 (32.26) | 519 (28.38) | ||
| ≥ 76 years old, n (%) | 696 (38.05) | 1608 (33.35) | 696 (38.05) | 821 (44.89) | ||
| Acute renal disease, n (%) | 463 (25.31) | 1025 (21.26) | < 0.001 | 463 (25.31) | 452 (24.71) | 0.675 |
| Chronic renal disease, n (%) | 514 (28.1) | 676 (14.02) | < 0.001 | 514 (28.1) | 457 (24.99) | 0.033 |
| Congestive heart failure, n (%) | 294 (16.07) | 432 (8.96) | < 0.001 | 294 (16.07) | 275 (15.04) | 0.386 |
| COPD, n (%) | 253 (13.83) | 448 (9.29) | < 0.001 | 253 (13.83) | 256 (14) | 0.886 |
| Dementia, n (%) | 31 (1.69) | 76 (1.58) | 0.732 | 31 (1.69) | 30 (1.64) | 0.897 |
| Atrial fibrillation, n (%) | 545 (29.8) | 1278 (26.51) | 0.007 | 545 (29.8) | 564 (30.84) | 0.494 |
| COVID-19, n (%) | 6 (0.33) | 26 (0.54) | 0.266 | 6 (0.33) | 3 (0.16) | 0.317 |
| Ischemic heart disease, n (%) | 506 (27.67) | 740 (15.35) | < 0.001 | 506 (27.67) | 477 (26.08) | 0.279 |
| Previous aortic valve disease, n (%) | 483 (26.41) | 1505 (31.22) | < 0.001 | 483 (26.41) | 483 (26.41) | 0.999 |
| Previous mitral valve disease, n (%) | 402 (21.98) | 1308 (27.13) | < 0.001 | 402 (21.98) | 383 (20.94) | 0.444 |
| Previous pulmonic valve disease, n (%) | 2 (0.11) | 12 (0.25) | 0.268 | 2 (0.11) | 1 (0.05) | 0.564 |
| Previous tricuspid valve disease, n (%) | 104 (5.69) | 342 (7.09) | 0.040 | 104 (5.69) | 88 (4.81) | 0.236 |
| Prosthetic valve carriers, n (%) | 173 (9.46) | 426 (8.84) | 0.429 | 173 (9.46) | 163 (8.91) | 0.567 |
| CCI index, mean (SD) | 1.47 (1.13) | 1.14 (1.07) | < 0.001 | 1.47 (1.13) | 1.39 (1.16) | 0.053 |
| Periannular complications / atrioventricular block, n (%) | 122 (6.67) | 288 (5.97) | 0.292 | 122 (6.67) | 96 (5.25) | 0.069 |
| Septic arterial embolism, n (%) | 67 (3.66) | 221 (4.58) | 0.099 | 67 (3.66) | 52 (2.84) | 0.162 |
| Cardiogenic shock, n (%) | 35 (1.91) | 126 (2.61) | 0.097 | 35 (1.91) | 45 (2.46) | 0.258 |
| Dialysis, n (%) | 118 (6.45) | 213 (4.42) | 0.001 | 118 (6.45) | 88 (4.81) | 0.031 |
| Heart valve surgery (aortic, mitral, tricuspid, pulmonary), n (%) | 336 (18.37) | 1123 (23.29) | < 0.001 | 336 (18.37) | 320 (17.5) | 0.490 |
| Mechanical ventilation, n (%) | 207 (11.32) | 545 (11.3) | 0.988 | 207 (11.32) | 192 (10.5) | 0.426 |
| Pacemaker implantation, n (%) | 121 (6.62) | 244 (5.06) | 0.013 | 121 (6.62) | 87 (4.76) | 0.015 |
| LOHS, Median (IQR) | 19 (25) | 20 (25) | 0.866 | 19 (25) | 19 (24) | 0.556 |
| IHM, n (%) | 302 (16.51) | 740 (15.35) | 0.244 | 302 (16.51) | 333 (18.21) | 0.176 |
T2DM: Type 2 diabetes mellitus; CCI: Charlson comorbidity index; COPD: chronic obstructive pulmonary disease; LOHS: Length of hospital stay; IHM: in-hospital mortality
Distribution of study covariates and hospital outcomes of MEN AND WOMEN with T2DM with infective endocarditis in Spain (2016–2020), before and after propensity score matching (PSM)
| BEFORE PSM | AFTER PSM | |||||
|---|---|---|---|---|---|---|
| T2DM Men | T2DM Women | p-value | T2DM Men | T2DM Women | p-value | |
| N, (incidence per 100,000 subjects per year) | 1829 (23.29) | 839 (11.91) | < 0.001 | 839 | 839 | NA |
| Age, mean (SD) | 71.61 (9.88) | 75.58 (9) | < 0.001 | 76.29 (7.65) | 75.58 (9) | 0.081 |
| 40–66 years old, n (%) | 543 (29.69) | 122 (14.54) | < 0.001 | 81 (9.65) | 122 (14.54) | 0.004 |
| 67–75 years old, n (%) | 590 (32.26) | 264 (31.47) | 302 (36) | 264 (31.47) | ||
| ≥ 76 years old, n (%) | 696 (38.05) | 453 (53.99) | 456 (54.35) | 453 (53.99) | ||
| Acute renal disease, n (%) | 463 (25.31) | 205 (24.43) | 0.626 | 200 (23.84) | 205 (24.43) | 0.775 |
| Chronic renal disease, n (%) | 514 (28.1) | 257 (30.63) | 0.181 | 247 (29.44) | 257 (30.63) | 0.594 |
| Congestive heart failure, n (%) | 294 (16.07) | 146 (17.4) | 0.391 | 133 (15.85) | 146 (17.4) | 0.394 |
| COPD, n (%) | 253 (13.83) | 35 (4.17) | < 0.001 | 40 (4.78) | 35 (4.17) | 0.554 |
| Dementia, n (%) | 31 (1.69) | 34 (4.05) | < 0.001 | 25 (2.98) | 34 (4.05) | 0.233 |
| Atrial fibrillation, n (%) | 545 (29.8) | 319 (38.02) | < 0.001 | 309 (36.83) | 319 (38.02) | 0.614 |
| COVID-19, n (%) | 6 (0.33) | 6 (0.72) | 0.165 | 6 (0.72) | 6 (0.72) | 0.999 |
| Ischemic heart disease, n (%) | 506 (27.67) | 114 (13.59) | < 0.001 | 132 (15.73) | 114 (13.59) | 0.214 |
| Previous aortic valve disease, n (%) | 483 (26.41) | 206 (24.55) | 0.309 | 192 (22.88) | 206 (24.55) | 0.422 |
| Previous mitral valve disease, n (%) | 402 (21.98) | 268 (31.94) | < 0.001 | 260 (30.99) | 268 (31.94) | 0.674 |
| Previous pulmonic valve disease, n (%) | 2 (0.11) | 2 (0.24) | 0.424 | 1 (0.12) | 2 (0.24) | 0.563 |
| Previous tricuspid valve disease, n (%) | 104 (5.69) | 94 (11.2) | < 0.001 | 73 (8.7) | 94 (11.2) | 0.087 |
| Prosthetic valve carriers, n (%) | 173 (9.46) | 83 (9.89) | 0.724 | 84 (10.01) | 83 (9.89) | 0.935 |
| CCI index, mean (SD) | 1.47 (1.13) | 1.41 (0.99) | 0.170 | 1.26 (1.05) | 1.41 (0.99) | 0.004 |
| Periannular complications / atrioventricular block, n (%) | 122 (6.67) | 45 (5.36) | 0.196 | 53 (6.32) | 45 (5.36) | 0.405 |
| Septic arterial embolism, n (%) | 67 (3.66) | 35 (4.17) | 0.525 | 34 (4.05) | 35 (4.17) | 0.902 |
| Cardiogenic shock, n (%) | 35 (1.91) | 14 (1.67) | 0.662 | 9 (1.07) | 14 (1.67) | 0.294 |
| Dialysis, n (%) | 118 (6.45) | 64 (7.63) | 0.263 | 41 (4.89) | 64 (7.63) | 0.020 |
| Heart valve surgery (aortic, mitral, tricuspid, pulmonary), n (%) | 336 (18.37) | 121 (14.42) | 0.012 | 123 (14.66) | 121 (14.42) | 0.890 |
| Mechanical ventilation, n (%) | 207 (11.32) | 87 (10.37) | 0.468 | 65 (7.75) | 87 (10.37) | 0.061 |
| Pacemaker implantation, n (%) | 121 (6.62) | 41 (4.89) | 0.083 | 50 (5.96) | 41 (4.89) | 0.332 |
| LOHS, Median (IQR) | 19 (25) | 18 (25) | 0.257 | 19 (26) | 18 (25) | 0.329 |
| IHM, n (%) | 302 (16.51) | 190 (22.65) | < 0.001 | 151 (18.00) | 190 (22.65) | 0.018 |
T2DM: Type 2 diabetes mellitus; CCI: Charlson comorbidity index; COPD: chronic obstructive pulmonary disease; LOHS: Length of hospital stay; IHM: in-hospital mortality
Multivariable analysis of factors associated with in-hospital mortality with infective endocarditis, among T2DM patients according to sex
| MEN | WOMEN | BOTH | |
|---|---|---|---|
| OR (95%CI) | OR (95%CI) | OR (95% CI) | |
| 40–66 years old | 1 | 1 | 1 |
| 67–75 years old | 1.34 (0.93–1.95) | 1.13 (0.61–2.09) | 1.04 (0.66–1.65) |
| ≥ 76 years old | 2.15 (1.5–3.09) | 1.8 (1.01–3.25) | 1.52 (0.97–2.36) |
| Acute renal disease | 2.33 (1.75–3.11) | 2.27 (1.52–3.4) | 2.01 (1.52–2.67) |
| Congestive heart failure | 1.52 (1.12–2.02) | 1.78 (1.21–3.02) | 1.61 (1.21–2.33) |
| Ischemic heart disease | NS | 1.64 (1.01–2.7) | 1.75 (1.19–2.58) |
| Septic arterial embolism | 2.52 (1.14–5.57) | 4.55 (2.1–9.85) | 2.88 (1.86–4.66) |
| Cardiogenic shock | 2.76 (1.25–6.1) | 6.99 (1.89–25.84) | 3.87 (1.48–10.12) |
| Dialysis | 2.27 (1.43–3.61) | 3.78 (2.03–7.05) | 2.21 (1.38–3.54) |
| Mechanical ventilation | 2.58 (1.74–3.81) | 3.16 (1.76–5.69) | 3.44 (2.26–5.23) |
| Pacemaker implantation | 0.29 (0.14–0.61) | NS | 0.44 (0.22–0.89) |
| Staphylococcus bacteremia | 1.33 (1.01–1.78) | NS | 1.47 (1.11–1.95) |
| Streptococcus bacteremia | 0.48 (0.31–0.76) | 0.57 (0.33–1) | 0.49 (0.32–0.73) |
| Female sex | NA | NA | 1.24 (1.02–1.59) |
Multivariable analysis of factors associated with in-hospital mortality with infective endocarditis, among all patients according to sex
| MEN | WOMEN | BOTH | |
|---|---|---|---|
| OR (95%CI) | OR (95%CI) | OR (95%CI) | |
| 40–66 years old | 1 | 1 | 1 |
| 67–75 years old | 1.34 (1.02–1.76) | 1.14 (0.73–1.78) | 1.35 (1.07–1.69) |
| ≥ 76 years old | 2.22 (1.71–2.89) | 1.87 (1.24–2.84) | 2.12 (1.7–2.64) |
| Acute renal disease | 2.12 (1.73–2.6) | 2.19 (1.65–2.9) | 1.98 (1.68–2.33) |
| Chronic renal disease | 1.22 (1.01–1.51) | 1.18 (1–1.39) | |
| Congestive heart failure | 1.96 (1.72–2.42) | 2.11 (1.79–3.20) | 2.01 (1.68–2.87 |
| Ischemic heart disease | 1.27 (1.04–1.55) | 1.41 (1.14–1.72) | 1.34 (1.11–1.57) |
| Septic arterial embolism | 3.73 (2.07–6.73) | 1.78 (1.24–2.56) | |
| Cardiogenic shock | 4.35 (2.59–7.28) | 5.5 (2.24–13.5) | 4.02 (2.58–6.25) |
| Dialysis | 1.8 (1.27–2.56) | 3.4 (2.07–5.58) | 1.91 (1.44–2.53) |
| Heart valve surgery (aortic, mitral, tricuspid, pulmonary) | 0.74 (0.56–0.97) | ||
| Mechanical ventilation | 3.49 (2.65–4.6) | 2.63 (1.73–4) | 3.06 (2.44–3.84) |
| Pacemaker implantation | 0.34 (0.2–0.57) | 0.34 (0.22–0.53) | |
| Staphylococcus bacteremia | 1.29 (1.05–1.58) | 1.49 (1.26–1.74) | |
| Streptococcus bacteremia | 0.44 (0.32–0.59) | 0.39 (0.26–0.58) | 0.43 (0.34–0.55) |
| Female sex | NA | NA | 1.31 (1.11–1.54) |
| T2DM | 0.87 (0.72–1.05) | 0.93 (0.72–1.2) | 0.92 (0.8–1.07) |
T2DM: Type 2 diabetes mellitus